Pharmacokinetics in the Geriatric Population

Referencias bibliográficas

• Burton, P.S., Goodwin, J.T., Vidmar, T.J., et al. Predicting drug absorption: How nature made it a difficult problem. J. Pharmacol. Exp. Ther. 2002; 303:889–895.
• Hurwitz, A., Brady, D.A., Schaal, S.E., et al. Gastric acidity in older adults. JAMA 1997; 278:659–662.
• Orr, W.C., Chen, C.L. Aging and neural control of the GI tract: IV. Clinical and physiological aspects of gastrointestinal motility and aging. Am. J. Physiol. 2002; 283:G1226–G1231.
• Gainsboroug, N., Maskrey, V.L., Nelson, M.L., et al. The association of age with gastric emptying. Age and Ageing 1993; 22:37–40.
• Firth, M., Prather, C.M. Gastrointestinal motility problems in the elderly patient. Gastroenterology 2002; 122:1688–1700.
• Saltzman, J.R., Kowdley, K.V., Perrone, G., et al. Changes in small intestine permeability with aging. J. Am. Geriatr. Soc. 1995; 43:160–164.
• Turnheim, K. Drug dosage in the elderly. Is it rational? Drugs & Aging 1998; 13(5): 357–379.
• Sacchi, V.F., Magagnin, S. Age-related modifications of leucine uptake in brush-border membrane vesicles from rat jejunum. Mech. Ageing Dev. 1992; 63:257–273.
• McLean, A.J., Le Couteur, D.G. Aging biology and geriatric clinical pharmacology. Pharmacol. Rev. 2004; 56:163–184.
• Wilkinson, G.R. The effects of diet, aging and disease-states on presystemic elimination and oral drug bioavailability in humans. Adv. Drug. Deliv. Rev. 1997; 27:129–159.
• Roskos, K.V., Maibach, H.I., Guy, R.A. The effect of aging on percutaneous absorption in man. J. Pharmacokinet. Biopharm. 1989; 17:617–630.
• Beaufrere, B., Morio, B. Fat and protein redistribution with aging: Metabolic considerations. Eur. J. Clin. Nutr. 2000; 54:S48–S53.
• Bressler, R., Bahl, J.J. Principles of drug therapy for the elderly patients. Mayo Clin. Proc. 2003; 78:1564–1577.
• Campion, E.W., deLabry, L.O., Glynn, R.J. The effect of age on serum albumin in healthy males: Report from the Normative Aging Study. J. Gerontol. 1988; 43:M18–M20.
• Wallace, S.M., Verbeek, R.K. Plasma protein binding in the elderly. Clin. Pharmacokinet. 1987; 12:41–72.
• Grandison, M.K., Boudinot, F.D. Age-related changes in protein binding of drugs: Implications for therapy. Clin. Pharmacokinet. 2000; 38:271–290.
• Benet, L.Z., Hoener, B.A. Changes in plasma protein binding have little clinical relevance. Clin. Pharmacol. Ther. 2002; 71:115–121.
• Mangoni, A.A., Jackson, S.H. Age-related changes in pharmacokinetics and pharmacodynamics: Basic principles and practical applications. Br. J. Clin. Pharmacol. 2004; 57(1):6–14.
• Schmucker, D.L. Liver function and phase I drug metabolism in the elderly. A paradox. Drugs & Aging 2001; 18:837–851.
• Bebia, Z., Buch, S.C., Wilson, J.W., et al. Bioequivalence revisited: Influence of age and sex on CYP enzimes. Clin. Pharmacol. Ther. 2004; 76:618–627.
• Ishizawa, Y., Yasui-Furukori, N., Takahata, T., et al. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics. Clin. Pharmacokinet. 2005; 44:1179–1189.
• Ginsberg, G., Hattis, D., Russ, A., et al. Pharmacokinetic and pharmacodynamic factors that can affect sensitivity to neurotoxic sequelae in elderly individuals. Environ. Health Perspect. 2005; 113:1243–1249.
• Zeeh, J., Platt, D. The aging liver. Structural and functional changes and their consequences for drug treatment in old age. Gerontology 2002; 48:121–127.
• Kinirons, M.T., O’Mahony, M.S. Drug metabolism and ageing. Br. J. Clin. Pharmacol. 2004; 57:540–544.
• Sotaniemi, E.A., Arranto, A.J., Pelkonen, O., et al. Age and cytochrome P450-linked drug metabolism in humans: An analysis of 226 subjects with equal histopathological conditions. Clin. Pharmacol. Ther. 1997; 61:331–339.
• Levey, A.S., Coresh, J., Balk, E., et al. National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease. Evaluation, classification and stratification. Ann. Intern. Med. 2003; 139:137–147.
• Bailie, G.R., Uhlig, K., Levey, A.S. Clinical practice guidelines in Nephrology: Evaluation, classification and stratification of chronic kidney disease. Pharmacotherapy 2005; 25:491–502.
• Cockcroft, D.W., Gault, M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31–41.
• Burkhardt, H., Bojarski, G., Gretz, N., et al. Creatinine clearance, Cockcroft–Gault formula and cystatin C: Estimators of true glomerular filtration rate in the elderly? Gerontology 2002; 48:140–146.
• Fliser, D., Ritz, E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am. J. Kidney Dis. 2001; 37:79–83.
• Tett, S.E., Kirkpatrick, C.M.J., Gross, A.S., et al. Principles and clinical application of assessing alterations in renal elimination pathways. Clin. Pharmacokinet. 2003; 6:45–65.
• Matzke, G.R., Comstock, T.J. Influence of renal function and dialysis on drug disposition. In Applied Pharmacokinetics and Pharmacodynamics, M.E. Burton, L.M. Shaw, J.J. Schentag, and W.E. Evans, eds. London: Lippincott Williams and Wilkins. 2006; pp. 187–212.
• Gabardi, S., Abramson, S. Drug dosing in chronic kidney disease. Med. Clin. N. Am. 2005; 89:649–687.
• Conway, B.R., Fogarty, D.G., Nelson, W.E., et al. Opiate toxicity in patients with renal failure. Br. Med. J. 2006; 332:345–346.
• Angst, M.S., Buhrer, M., Lotsch, J. Insidious intoxication after morphine treatment in renal failure: Delayed onset of morphine-6-glucuronide action. Anesthesiology 2000; 92:1473–1476.
• Gelman, R.S., Taylor, S.G.T. Cyclophosphamide, metotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: The elimination of age trend in toxicity by using dosed based on creatinine clearance. J. Clin. Onc. 1984; 2:1404–1413.
• Pillans, P.I., Landsberg, P.G., Fleming, A.M., et al. Evaluation of dosage adjustment in patients with renal impairment. Int. Med. J. 2003; 33:10–13.
• McCormack, J.P., Cooper, J., Carleton, B. Simple approach to dosage adjustment in patients with renal impairment. Am. J. Health Syst. Pharm. 1997; 54:2505–2509.